Abstract
Multiple myeloma (MM) is a hematologic malignancy characterized by abnormal proliferation of immunoglobulin-secreting plasma cells. Manifestations of MM may include anemia, osteolytic lesions, and renal dysfunction. Treatment for this disease chiefly consists of corticosteroids, bisphosphonates, chemotherapy, and hematopoietic stem-cell transplantation. This medical management update will review recent clinical and therapeutic advances in the field of MM and highlight issues that are important to the oral health care provider.
MeSH terms
-
Adrenal Cortex Hormones / therapeutic use
-
Angiogenesis Inhibitors / therapeutic use
-
Anti-Inflammatory Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bone Density Conservation Agents / adverse effects
-
Bone Density Conservation Agents / therapeutic use
-
Boronic Acids / therapeutic use
-
Bortezomib
-
Dental Care for Chronically Ill*
-
Diphosphonates / adverse effects
-
Diphosphonates / therapeutic use
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Jaw Diseases / chemically induced
-
Jaw Neoplasms / secondary
-
Multiple Myeloma / complications
-
Multiple Myeloma / diagnosis
-
Multiple Myeloma / pathology
-
Multiple Myeloma / therapy*
-
Oral Hemorrhage / etiology
-
Osteonecrosis / chemically induced
-
Protease Inhibitors / therapeutic use
-
Proteasome Inhibitors
-
Pyrazines / therapeutic use
-
Thalidomide / therapeutic use
Substances
-
Adrenal Cortex Hormones
-
Angiogenesis Inhibitors
-
Anti-Inflammatory Agents
-
Bone Density Conservation Agents
-
Boronic Acids
-
Diphosphonates
-
Protease Inhibitors
-
Proteasome Inhibitors
-
Pyrazines
-
Thalidomide
-
Bortezomib